{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T13:53:22Z","timestamp":1791726802760,"version":"4.3.4"},"reference-count":64,"publisher":"American Society of Hematology","issue":"12","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,6,23]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Imatinib, the first tyrosine kinase inhibitor (TKI) for the treatment of chronic myeloid leukemia (CML), improves overall survival (OS), but the introduction of newer TKIs requires the definition of the optimal first-line TKI for newly diagnosed Philadelphia chromosome\u2013positive (Ph+) chronic-phase (CP) CML. This systematic review of randomized controlled trials (RCTs) compares the efficacy and safety of imatinib vs second-generation (dasatinib, nilotinib, bosutinib) and third-generation TKIs (ponatinib) in adults with newly diagnosed Ph+ CP CML, concentrating on OS, progression-free survival (PFS), and hematological and nonhematological adverse events. The quality of the evidence was assessed using the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) method. Seven RCTs published between 1990 and 2019 (involving 3262 participants) satisfied the eligibility criteria. Two RCTs (imatinib vs nilotinib and imatinib vs dasatinib) found no difference in 5-year OS or PFS. Second- and third-generation TKIs improved 3-month major molecular responses (relative risk [RR], 4.28; 95% confidence interval [CI], 2.20-8.32) and other efficacy outcomes, decreased accelerated\/blastic-phase transformations (RR, 0.44; 95% CI, 0.26-0.74), but were associated with more cases of thrombocytopenia (RR, 1.57; 95% CI, 1.20-2.05), cardiovascular events (RR, 2.54; 95% CI, 1.49-4.33), and pancreatic (RR, 2.29; 95% CI, 1.32-3.96) and hepatic effects (RR, 3.51; 95% CI 1.55-7.92). GRADE showed that the certainty of the evidence ranged from high to moderate. This study shows that, in comparison with imatinib, second- and third-generation TKIs improve clinical responses, but the safer toxicity profile of imatinib may make it a better option for patients with comorbidities.<\/jats:p>","DOI":"10.1182\/bloodadvances.2019001329","type":"journal-article","created":{"date-parts":[[2020,6,19]],"date-time":"2020-06-19T15:39:44Z","timestamp":1592581184000},"page":"2723-2735","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":131,"title":["First-line imatinib vs second- and third-generation TKIs for chronic-phase CML: a systematic review and meta-analysis"],"prefix":"10.1182","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7351-8634","authenticated-orcid":false,"given":"Claudia","family":"Vener","sequence":"first","affiliation":[{"name":"Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy;"},{"name":"Analytical Epidemiology and Health Impact Unit, Department of Research, National Tumour Institute of Milan, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Foundation, Milan, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2211-3300","authenticated-orcid":false,"given":"Rita","family":"Banzi","sequence":"first","affiliation":[{"name":"Centre for Health Regulatory Policies, Istituto di Ricerche Farmacologiche Mario Negri, IRCCS, Milan, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9358-011X","authenticated-orcid":false,"given":"Federico","family":"Ambrogi","sequence":"first","affiliation":[{"name":"G. A. Maccacaro Laboratory, Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annalisa","family":"Ferrero","sequence":"first","affiliation":[{"name":"Martini Hospital, Turin, Italy; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1046-3514","authenticated-orcid":false,"given":"Giuseppe","family":"Saglio","sequence":"first","affiliation":[{"name":"Department of Clinical and Biological Sciences, University of Turin, Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4843-4663","authenticated-orcid":false,"given":"Gabriella","family":"Pravettoni","sequence":"first","affiliation":[{"name":"Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milena","family":"Sant","sequence":"first","affiliation":[{"name":"Analytical Epidemiology and Health Impact Unit, Department of Research, National Tumour Institute of Milan, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Foundation, Milan, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2020,6,19]]},"reference":[{"issue":"3","key":"2020061914292423000_B1","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1056\/NEJM199907153410306","article-title":"The biology of chronic myeloid leukemia","volume":"341","author":"Faderl","year":"1999","journal-title":"N Engl J Med"},{"issue":"19","key":"2020061914292423000_B2","doi-asserted-by":"crossref","first-page":"3724","DOI":"10.1182\/blood-2010-05-282632","article-title":"Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project","volume":"116","author":"Sant","year":"2010","journal-title":"Blood"},{"issue":"6","key":"2020061914292423000_B3","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1038\/leu.2015.73","article-title":"The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European Countries","volume":"29","author":"Hoffmann","year":"2015","journal-title":"Leukemia"},{"issue":"14","key":"2020061914292423000_B4","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","article-title":"Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia","volume":"344","author":"Druker","year":"2001","journal-title":"N Engl J Med"},{"key":"2020061914292423000_B5","unstructured":"European Commission\n          . Glivec. Appendix I: summary of product characteristics [in Italian]. https:\/\/ec.europa.eu\/health\/documents\/community-register\/2017\/20170508137859\/anx_137859_it.pdf. Accessed 5 June 2020."},{"issue":"19","key":"2020061914292423000_B6","doi-asserted-by":"crossref","first-page":"3898","DOI":"10.1182\/blood-2012-02-410688","article-title":"A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemia","volume":"120","author":"Radich","year":"2012","journal-title":"Blood"},{"issue":"24","key":"2020061914292423000_B7","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","article-title":"Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia","volume":"362","author":"Kantarjian","year":"2010","journal-title":"N Engl J Med"},{"issue":"3","key":"2020061914292423000_B8","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/ejh.12423","article-title":"Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: clinical results from a randomised phase-2 study (NordCML006)","volume":"94","author":"Hjorth-Hansen","year":"2015","journal-title":"Eur J Haematol"},{"issue":"24","key":"2020061914292423000_B9","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","article-title":"Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia","volume":"362","author":"Saglio","year":"2010","journal-title":"N Engl J Med"},{"key":"2020061914292423000_B10","unstructured":"European Medicines Agency\n          . Sprycel. Appendix I: summary of product characteristics [in Italian]. http:\/\/www.ema.europa.eu\/docs\/it_IT\/document_library\/EPAR_-_Product_Information\/human\/000709\/WC500056998.pdf. Accessed 5 June 2020."},{"key":"2020061914292423000_B11","unstructured":"European Commission\n          . Tasigna. Appendix I: summary of product characteristics [in Italian]. https:\/\/ec.europa.eu\/health\/documents\/community-register\/2017\/20170524137917\/anx_137917_it.pdf. Accessed 5 June 2020."},{"key":"2020061914292423000_B12","unstructured":"European Commission\n          . Bosulif. Appendix I: summary of product characteristics [in Italian]. https:\/\/ec.europa.eu\/health\/documents\/community-register\/2013\/20130327125474\/anx_125474_it.pdf. Accessed 5 June 2020."},{"issue":"28","key":"2020061914292423000_B13","doi-asserted-by":"crossref","first-page":"3486","DOI":"10.1200\/JCO.2011.38.7522","article-title":"Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial","volume":"30","author":"Cortes","year":"2012","journal-title":"J Clin Oncol"},{"issue":"3","key":"2020061914292423000_B14","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1200\/JCO.2017.74.7162","article-title":"Bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia: results from the randomized BFORE trial","volume":"36","author":"Cortes","year":"2018","journal-title":"J Clin Oncol"},{"key":"2020061914292423000_B15","unstructured":"European Commission\n          . Iclusig. Appendix I: summary of product characteristics [in Italian]. https:\/\/ec.europa.eu\/health\/documents\/community-register\/2016\/20160825135744\/anx_135744_it.pdf. Accessed 5 June 2020."},{"issue":"5","key":"2020061914292423000_B16","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/S1470-2045(16)00080-2","article-title":"Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial","volume":"17","author":"Lipton","year":"2016","journal-title":"Lancet Oncol"},{"issue":"10","key":"2020061914292423000_B17","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1056\/NEJMoa1609324","article-title":"Long-term outcomes of imatinib treatment for chronic myeloid leukemia","volume":"376","author":"Hochhaus","year":"2017","journal-title":"N Engl J Med"},{"issue":"4","key":"2020061914292423000_B18","doi-asserted-by":"crossref","first-page":"896","DOI":"10.3109\/10428194.2014.947610","article-title":"Is survival in myeloid malignancies really improving? A retrospective 15-year population-based study","volume":"56","author":"Osca-Gelis","year":"2015","journal-title":"Leuk Lymphoma"},{"issue":"9","key":"2020061914292423000_B19","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/S1470-2045(14)70282-7","article-title":"Survival for haematological malignancies in Europe between 1997 and 2008 by region and age: results of EUROCARE-5, a population-based study","volume":"15","author":"Sant","year":"2014","journal-title":"Lancet Oncol"},{"issue":"8","key":"2020061914292423000_B20","doi-asserted-by":"crossref","first-page":"764.e1","DOI":"10.1016\/j.amjmed.2010.03.018","article-title":"Age disparity in the dissemination of imatinib for treating chronic myeloid leukemia","volume":"123","author":"Wiggins","year":"2010","journal-title":"Am J Med"},{"key":"2020061914292423000_B21","doi-asserted-by":"crossref","first-page":"iv41","DOI":"10.1093\/annonc\/mdx219","article-title":"Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Hochhaus","year":"2017","journal-title":"Ann Oncol"},{"issue":"9","key":"2020061914292423000_B22","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.6004\/jnccn.2018.0071","article-title":"Chronic myeloid leukemia, version 1.2019, NCCN Clinical Practice Guidelines in Oncology","volume":"16","author":"Radich","year":"2018","journal-title":"J Natl Compr Canc Netw"},{"key":"2020061914292423000_B23","unstructured":"National Institute for Health Research\n          . PROSPERO: international prospective register of systematic reviews.https:\/\/www.crd.york.ac.uk\/PROSPERO\/. Accessed 5 June 2020."},{"key":"2020061914292423000_B24","unstructured":"Cochrane. https:\/\/www.cochrane.org\/. Accessed 5 June 2020."},{"key":"2020061914292423000_B25","unstructured":"PRISMA\n          . PRISMA checklist.http:\/\/prisma-statement.org\/PRISMAStatement\/Checklist. Accessed 5 June 2020."},{"issue":"6","key":"2020061914292423000_B26","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1182\/blood-2006-02-005686","article-title":"Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet","volume":"108","author":"Baccarani","year":"2006","journal-title":"Blood"},{"key":"2020061914292423000_B27","unstructured":"Cochrane. Cochrane methods: bias. http:\/\/methods.cochrane.org\/bias\/assessing-risk-bias-included-studies. Accessed 5 June 2020."},{"key":"2020061914292423000_B28","unstructured":"GRADEpro\n          . GRADEpro GDT.https:\/\/gradepro.org\/. Accessed 5 June 2020."},{"issue":"21","key":"2020061914292423000_B29","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V116.21.206.206","article-title":"Dasatinib versus imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) in the DASISION trial: 18-month follow-up [abstract]","volume":"116","author":"Shah","year":"2010","journal-title":"Blood"},{"issue":"15","key":"2020061914292423000_B30","article-title":"Dasatinib or imatinib (IM) in newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): two-year follow-up from DASISION [abstract]","volume":"29","author":"Kantarjian","year":"2011","journal-title":"J Clin Oncol"},{"issue":"21","key":"2020061914292423000_B31","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V118.21.2767.2767","article-title":"Dasatinib and imatinib-induced reductions in BCR-ABL transcript levels below 10% at 3 months are associated with improved responses in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): analysis of molecular response kinetics in the DASISION trial [abstract]","volume":"118","author":"Hochhaus","year":"2011","journal-title":"Blood"},{"issue":"15","key":"2020061914292423000_B32","article-title":"Dasatinib versus imatinib (IM) in newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): DASISION 3-year follow-up [abstract]","volume":"30","author":"Hochhaus","year":"2012","journal-title":"J Clin Oncol"},{"issue":"5","key":"2020061914292423000_B33","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1182\/blood-2011-08-376087","article-title":"Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)","volume":"119","author":"Kantarjian","year":"2012","journal-title":"Blood"},{"issue":"4","key":"2020061914292423000_B34","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1182\/blood-2013-06-511592","article-title":"Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION)","volume":"123","author":"Jabbour","year":"2014","journal-title":"Blood"},{"issue":"21","key":"2020061914292423000_B35","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V122.21.653.653","article-title":"Four-year (yr) follow-up of patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) receiving dasatinib or imatinib: efficacy based on early response [abstract]","volume":"122","author":"Cortes","year":"2013","journal-title":"Blood"},{"issue":"21","key":"2020061914292423000_B36","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V124.21.152.152","article-title":"Final study results of the phase 3 dasatinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) trial (DASISION, CA180-056) [abstract]","volume":"124","author":"Cortes","year":"2014","journal-title":"Blood"},{"issue":"20","key":"2020061914292423000_B37","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1200\/JCO.2015.64.8899","article-title":"Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-na\u00efve chronic myeloid leukemia patients trial","volume":"34","author":"Cortes","year":"2016","journal-title":"J Clin Oncol"},{"issue":"7","key":"2020061914292423000_B38","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1038\/leu.2013.19","article-title":"Impact of malignant stem cell burden on therapy outcome in newly diagnosed chronic myeloid leukemia patients","volume":"27","author":"Mustjoki","year":"2013","journal-title":"Leukemia"},{"issue":"21","key":"2020061914292423000_B39","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V122.21.4032.4032","article-title":"Dasatinib treatment induces fast and deep responses in newly diagnosed chronic myeloid leukemia (CML) patients in chronic phase: clinical results from a randomised phase-2 study (NordCML006) [abstract]","volume":"122","author":"Hjorth-Hansen","year":"2013","journal-title":"Blood"},{"issue":"15","key":"2020061914292423000_B40","article-title":"Comparison of nilotinib and imatinib in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): ENESTnd beyond one year [abstract]","volume":"28","author":"Larson","year":"2010","journal-title":"J Clin Oncol"},{"issue":"21","key":"2020061914292423000_B41","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V116.21.207.207","article-title":"ENESTnd update: continued superiority of nilotinib versus imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) [abstract]","volume":"116","author":"Hughes","year":"2010","journal-title":"Blood"},{"issue":"9","key":"2020061914292423000_B42","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/S1470-2045(11)70201-7","article-title":"Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial","volume":"12","author":"Kantarjian","year":"2011","journal-title":"Lancet Oncol"},{"issue":"21","key":"2020061914292423000_B43","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V120.21.1676.1676","article-title":"Enestnd 4-year (y) update: continued superiority of nilotinib vs imatinib in patients (pts) with newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia in chronic phase (CML-CP) [abstract]","volume":"120","author":"Kantarjian","year":"2012","journal-title":"Blood"},{"issue":"10","key":"2020061914292423000_B44","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1038\/leu.2012.134","article-title":"Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up [published correction appears in Leukemia. 2012;26(10):2302]","volume":"26","author":"Larson","year":"2012","journal-title":"Leukemia"},{"issue":"18","key":"2020061914292423000_B45","doi-asserted-by":"crossref","first-page":"3703","DOI":"10.1182\/blood-2012-04-423418","article-title":"Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase","volume":"121","author":"Hochhaus","year":"2013","journal-title":"Blood"},{"issue":"9","key":"2020061914292423000_B46","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1182\/blood-2013-06-510396","article-title":"Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib","volume":"123","author":"Hughes","year":"2014","journal-title":"Blood"},{"issue":"5","key":"2020061914292423000_B47","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1038\/leu.2016.5","article-title":"Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial","volume":"30","author":"Hochhaus","year":"2016","journal-title":"Leukemia"},{"issue":"23","key":"2020061914292423000_B48","article-title":"Impact of treatment with frontline nilotinib (NIL) vs imatinib (IM) on sustained deep molecular response (MR) in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) [abstract]","volume":"126","author":"Hochhaus","year":"2015","journal-title":"Blood"},{"key":"2020061914292423000_B49","author":"Hughes"},{"issue":"suppl 15","key":"2020061914292423000_B50","article-title":"Bosutinib (BOS) versus imatinib (IM) in patients (pts) with chronic phase chronic myeloid leukemia (CP CML) in the BELA trial: 18-month follow-up [abstract]","volume":"29","author":"Gambacorti-Passerini","year":"2011","journal-title":"J Clin Oncol"},{"issue":"1","key":"2020061914292423000_B51","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/bjh.13108","article-title":"Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukaemia: results from the 24-month follow-up of the BELA trial","volume":"168","author":"Br\u00fcmmendorf","year":"2015","journal-title":"Br J Haematol"},{"issue":"suppl 1","key":"2020061914292423000_B52","article-title":"Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukaemia: 30-month update of the BELA trial [abstract]","volume":"97","author":"Br\u00fcmmendorf","year":"2012","journal-title":"Haematologica"},{"issue":"10","key":"2020061914292423000_B53","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1002\/ajh.23788","article-title":"Safety of bosutinib versus imatinib in the phase 3 BELA trial in newly diagnosed chronic phase chronic myeloid leukemia","volume":"89","author":"Gambacorti-Passerini","year":"2014","journal-title":"Am J Hematol"},{"issue":"6","key":"2020061914292423000_B54","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1002\/ajh.24360","article-title":"Long-term evaluation of cardiac and vascular toxicity in patients with Philadelphia chromosome-positive leukemias treated with bosutinib","volume":"91","author":"Cortes","year":"2016","journal-title":"Am J Hematol"},{"issue":"1","key":"2020061914292423000_B55","article-title":"Bosutinib vs imatinib for newly diagnosed chronic myeloid leukaemia (CML) in the BFORE trial: 18-month follow-up [abstract]","volume":"130","author":"Gambacorti-Passerini","year":"2017","journal-title":"Blood"},{"issue":"24","key":"2020061914292423000_B56","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1002\/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8","article-title":"Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints","volume":"17","author":"Parmar","year":"1998","journal-title":"Stat Med"},{"key":"2020061914292423000_B57","doi-asserted-by":"crossref","first-page":"j4530","DOI":"10.1136\/bmj.j4530","article-title":"Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13","volume":"359","author":"Davis","year":"2017","journal-title":"BMJ"},{"key":"2020061914292423000_B58","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/2162-3619-2-5","article-title":"The relative efficacy of imatinib, dasatinib and nilotinib for newly diagnosed chronic myeloid leukemia: a systematic review and network meta-analysis","volume":"2","author":"Mealing","year":"2013","journal-title":"Exp Hematol Oncol"},{"issue":"1","key":"2020061914292423000_B59","doi-asserted-by":"crossref","first-page":"95","DOI":"10.3324\/haematol.2012.063172","article-title":"Has the time for first-line treatment with second generation tyrosine kinase inhibitors in patients with chronic myelogenous leukemia already come? Systematic review and meta-analysis","volume":"98","author":"Gurion","year":"2013","journal-title":"Haematologica"},{"issue":"2","key":"2020061914292423000_B60","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.ctrv.2013.09.004","article-title":"Major molecular response during the first year of dasatinib, imatinib or nilotinib treatment for newly diagnosed chronic myeloid leukemia: a network meta-analysis","volume":"40","author":"Signorovitch","year":"2014","journal-title":"Cancer Treat Rev"},{"issue":"6","key":"2020061914292423000_B61","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1002\/ijc.29889","article-title":"Tyrosine kinase inhibitors as a first-line treatment in patients with newly diagnosed chronic myeloid leukemia in chronic phase: a mixed-treatment comparison","volume":"138","author":"Firwana","year":"2016","journal-title":"Int J Cancer"},{"issue":"6","key":"2020061914292423000_B62","doi-asserted-by":"crossref","first-page":"e85","DOI":"10.1016\/j.clml.2016.03.003","article-title":"Comparative effectiveness of newer tyrosine kinase inhibitors versus imatinib in the first-line treatment of chronic-phase chronic myeloid leukemia across risk groups: a systematic review and meta-analysis of eight randomized Trials","volume":"16","author":"Yun","year":"2016","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2020061914292423000_B63","doi-asserted-by":"crossref","first-page":"3891","DOI":"10.2147\/CMAR.S177566","article-title":"First-line treatment strategies for newly diagnosed chronic myeloid leukemia: a network meta-analysis","volume":"10","author":"Chen","year":"2018","journal-title":"Cancer Manag Res"},{"issue":"5","key":"2020061914292423000_B64","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1001\/jamaoncol.2015.5932","article-title":"Association between BCR-ABL tyrosine kinase inhibitors for chronic myeloid leukemia and cardiovascular events, major molecular response, and overall survival: a systematic review and meta-analysis","volume":"2","author":"Douxfils","year":"2016","journal-title":"JAMA Oncol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/4\/12\/2723\/1745564\/advancesadv2019001329.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/4\/12\/2723\/1745564\/advancesadv2019001329.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,19]],"date-time":"2020-06-19T18:29:49Z","timestamp":1592591389000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/4\/12\/2723\/461024\/Firstline-imatinib-vs-second-and-thirdgeneration"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,19]]},"references-count":64,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,6,23]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2019001329","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,19]]}}}